Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanFRA:L74 -4.46%55 Debt-to-Equity is 0.08 as of Dec. 2025, which is at its 10-year median of 0.08. GuruFocus rates FRA:L74 with a GF Score™ of 55/100. The stock has 3 warning signs investors should review. Among 181 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 84.53% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for WuXi XDC Cayman's Debt-to-Equity or its related term are showing as below:
FRA:L74'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.08 Max: 1.18
Current: 0.05
During the past 6 years, the highest Debt-to-Equity Ratio of WuXi XDC Cayman was 1.18. The lowest was 0.00. And the median was 0.08.
FRA:L74's Debt-to-Equity is ranked better than 84.53% of 181
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.27
vs FRA:L74: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
WuXi XDC Cayman Debt-to-Equity Related Terms
WuXi XDC Cayman Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:L74 vs TMO, DHR, NTRA: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (FRA:L74) has a Debt-to-Equity of 0.08 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 0.08. According to the industry distribution chart, WuXi XDC Cayman ranks #28 out of 181 companies in the Medical Diagnostics & Research industry, placing it in the top 15.5%.
Is WuXi XDC Cayman's Debt-to-Equity too high?
WuXi XDC Cayman's current Debt-to-Equity of 0.08 is near median its 10-year median of 0.08. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.27. WuXi XDC Cayman's value of 0.08 is 70.4% below this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #28 out of 181 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #28 out of 181 companies for Debt-to-Equity. This places WuXi XDC Cayman in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. WuXi XDC Cayman's value of 0.08 is 70.4% below this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 0.27, WuXi XDC Cayman has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.27, based on 181 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current Debt-to-Equity of 0.08 is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current Debt-to-Equity is 0.08, which is near median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (FRA:L74) has a current Debt-to-Equity of 0.08. The current Debt-to-Equity is 0.08, which is near median its 10-year median of 0.08 and 70.4% below the Medical Diagnostics & Research industry median of 0.27. WuXi XDC Cayman's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For WuXi XDC Cayman (FRA:L74), the current Debt-to-Equity is 0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
55GF Score
Get the complete analysis for FRA:L74
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L74 has been successfully added to your 
